Motus GI Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Motus GI Holdings, Inc.

Motus GI Holdings, Inc. is a U.S.-based medical device company listed on the Nasdaq Capital Market in the United States under the ticker MOTS. The company operates in the gastrointestinal endoscopy niche, with its core value proposition centered on improving colon cleansing during colonoscopy in order to help reduce incomplete procedures, repeat exams, and clinical inefficiencies. Incorporated in Delaware in September 2016, Motus GI built its platform around the proprietary Pure-Vu System, which has received FDA 510(k) clearance and CE Mark approval in Europe for certain product generations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1686850/000121390021015694/f10k2020_motusgiholdings.htm?utm_source=openai)) From an operating perspective, Motus GI is a medical technology company focused on endoscopy solutions that improve clinical outcomes and the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. Its business model has historically been centered on developing, commercializing, and iterating devices designed to assist with difficult or poorly prepared colonoscopy procedures, a clinically recognized unmet need in hospital and inpatient settings. The company has described the evolution of its product line through a second-generation Pure-Vu platform and, more recently, commercial activity around the Pure-Vu EVS System. That suggests a strategy built on product refreshes and broader procedural adoption, although the company remains a specialized, niche player rather than a large-scale diversified medtech platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1686850/000121390020007971/f10k2019_motusgiholdings.htm?utm_source=openai)) Historically, Motus GI was created to address the limitations of colonoscopy when bowel preparation is inadequate. The company previously highlighted Fort Lauderdale, Florida, as its headquarters, and later announced a move of its corporate headquarters to the Greater Boston area in 2020 to improve collaboration and operational efficiency. Its geographic footprint is international at the industrial level, with legacy subsidiaries and activities linked to both the United States and Israel. ([nasdaq.com](https://www.nasdaq.com/press-release/motus-gi-moving-corporate-headquarters-to-greater-boston-area-to-foster-closer?utm_source=openai)) In competitive terms, Motus GI operates in a highly specialized segment where differentiation depends on clinical utility, ease of use, and economic value to providers. Compared with large endoscopy and gastrointestinal device manufacturers, it is a relatively small innovator with a focused solution set rather than a broad product portfolio. Recent notable corporate events include a February 2024 warrant exercise transaction that generated approximately $2.7 million in gross proceeds, underscoring that the company continues to rely on capital-market funding. For equity investors, the ongoing stream of SEC Form 4 insider transactions is relevant because it can provide signals on management and insider alignment in a stock that has historically been volatile and financing-sensitive. ([nasdaq.com](https://www.nasdaq.com/press-release/motus-gi-holdings-inc.-announces-exercise-of-warrants-for-%242.7-million-gross-proceeds?utm_source=openai))